Sun Pharmaceutical Industries Limited has received updated credit rating assessments from both CRISIL and ICRA. The ratings for the company’s long-term and short-term bank facilities and commercial paper remain high, with CRISIL placing its long-term rating on ‘Rating Watch with Developing Implications’ following the 27 April 2026 announcement regarding the acquisition of Organon & Co. ICRA has reaffirmed its existing ratings for the company, maintaining a stable outlook.
Credit Rating Performance
Sun Pharmaceutical Industries Limited has undergone a credit rating review following its recent strategic growth initiatives. CRISIL Ratings Limited has reaffirmed the long-term bank facilities at ‘Crisil AAA’ and short-term facilities and commercial paper at ‘Crisil A1+’. Concurrently, ICRA Limited has reaffirmed the company’s long-term rating at ‘[ICRA]AAA(Stable)’ and short-term rating at ‘[ICRA]A1+’.
Impact of Organon & Co. Acquisition
The rating activity follows the company’s 27 April 2026 announcement regarding a definitive agreement to acquire Organon & Co. In light of this development, CRISIL has placed the long-term ‘Crisil AAA’ rating on ‘Rating Watch with Developing Implications’. This status is a standard procedural step taken while the agency conducts a comprehensive assessment of the acquisition’s financial impact on the company. CRISIL intends to remove the rating from ‘Watch’ and issue a final rating action upon completion of this evaluation.
Stability Outlook
While CRISIL performs its deeper assessment of the acquisition, ICRA Limited has maintained its current rating stance, noting the announcement in its review. The reaffirmation of the highest-tier ratings from these leading agencies underscores the company’s robust financial position and market standing as it navigates this significant acquisition phase.
Source: BSE
